Workflow
药明康德(603259):业绩超市场预期 上修25年全年收入指引、维持重点推荐
Xin Lang Cai Jing·2025-10-28 00:31

Core Insights - The company reported strong financial performance for Q1-3 2025, with revenue of 32.86 billion yuan, a year-on-year increase of 18.6%, and a net profit attributable to shareholders of 12.08 billion yuan, up 84.8% [1] - The company plans to sell assets for a total of 2.8 billion yuan, transferring 100% equity of two subsidiaries [1] Financial Performance - For Q1-3 2025, the company achieved revenue of 32.45 billion yuan from continuing operations, a year-on-year growth of 22.51%, with Q3 alone generating 12.05 billion yuan, up 19.7% [2] - Adjusted net profit attributable to shareholders for Q1-3 2025 was 10.54 billion yuan, reflecting a 43.4% increase, with Q3 adjusted net profit at 4.22 billion yuan, up 42.0% [2] - As of September 2025, the company had a backlog of orders amounting to 59.88 billion yuan, a 41.2% year-on-year increase, indicating a solid foundation for future growth [2] Business Segments - The TIDES business segment reported revenue of 7.84 billion yuan for Q1-3 2025, a significant year-on-year increase of 121.1%, with Q3 revenue at 2.81 billion yuan, up 91.9% [3] - The chemical D&M business generated revenue of 14.24 billion yuan in Q1-3 2025, a 14.1% increase, with Q3 revenue at 5.56 billion yuan, up 9.2% [3] - The laboratory testing and analysis business achieved revenue of 2.96 billion yuan, growing 2.7% year-on-year, while the biology business reached 1.95 billion yuan, up 6.6% [4] Future Outlook - The company has revised its revenue guidance for 2025, increasing the expected growth rate for continuing operations from 13%-17% to 17%-18%, and overall revenue expectations from 42.5-43.5 billion yuan to 43.5-44 billion yuan [2] - The company anticipates continued growth in the laboratory segment due to improving market conditions [4] Investment Considerations - The company adjusted its revenue forecasts for 2025-2027, increasing expected revenues to 44.98 billion yuan, 52.42 billion yuan, and 61.15 billion yuan respectively, with corresponding EPS adjustments [5]